Ending Tobacco Use Through Interactive Tailored Messaging for Cambodian People Living With HIV/AIDS (Project END-IT)
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Behavioral, Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The goal of this research study is to test how well an automated text messaging smoking treatment program helps smokers with HIV quit smoking.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• 1\) being aged ≥18 years
• 2\) being HIV-positive
• 3\) self-reporting as a current combustible cigarette smoker (smoked ≥100 cigarettes in lifetime and currently smoke ≥1 cigarettes/day)
• 4\) willing to set a date for a quit attempt within 2 weeks of study enrollment
• 5\) being able to provide written informed consent to participate
• 6\) being able to read Khmer (score ≥4 points on the Rapid Estimate of Adult Literacy in Medicine-Short Form
Locations
Other Locations
Cambodia
National AIDS Authority
RECRUITING
Phnom Penh
National Center for HIV/AIDS, Dermatology and STD
RECRUITING
Phnom Penh
National Institute of Public Health
RECRUITING
Phnom Penh
Contact Information
Primary
Sarah Jones
Sarah.Jones@moffitt.org
813-745-7525
Time Frame
Start Date: 2023-01-11
Estimated Completion Date: 2027-02-28
Participants
Target number of participants: 800
Treatments
Active_comparator: Standard Care Group
Participants will receive brief advice and education materials to quit smoking along with brief weekly assessments to be completed on a smartphone. They will also receive a 8 week supply of of nicotine replacement therapy in the form of nicotine patches.
Experimental: Automated Messaging Treatment Group
Participants will receive brief advice and education materials to quit smoking, along with brief weekly assessments and an interactive phone-based treatment program delivered on a smartphone. They will also receive a 8 week supply of of nicotine replacement therapy in the form of nicotine patches.
Related Therapeutic Areas
Sponsors
Leads: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: University of Oklahoma, National Cancer Institute (NCI), M.D. Anderson Cancer Center